Merck settles tax dispute with IRS for $2.3 billion

Share this article:
Merck has entered an agreement to settle its previously disclosed tax disputes with the Internal Revenue service for $2.3 billion. The settlement essentially brings to a close the IRS’s examination of the company for the period 1993-2001, the Whitehouse Station, NJ drugmaker said in a statement issued today. The figure of $2.3 billion will cover federal tax and net interest after deductions and penalties, Merck said. The IRS' examination of years subsequent to 2001 remains open. Merck announced in November that it faced potential tax liabilities totaling $5.58 billion from US and Canadian authorities related to disputes over accounting for past transactions.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.